drugset / Trial / NCT00052624

Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma

NCT00052624 ↗

Phase 1 Unknown Xenova Biomedix
Open-labelTreatment

Summary

RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for glioblastoma multiforme and anaplastic astrocytoma. PURPOSE: Phase I trial to study the effectiveness of immunotoxin therapy in treating children who have progressive or recurrent glioblastoma multiforme or anaplastic astrocytoma

Timeline

Start
2002-07
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject transferrin-CRM107 Unknown — Other